Improved web-based calculators for predicting breast carcinoma outcomes
- 290 Downloads
We describe a set of web-based calculators, available at http://www.CancerMath.net, which estimate the risk of breast carcinoma death, the reduction in life expectancy, and the impact of various adjuvant treatment choices. The published SNAP method of the binary biological model of cancer metastasis uses information on tumor size, nodal status, and other prognostic factors to accurately estimate of breast cancer lethality at 15 years after diagnosis. By combining these 15-year lethality estimates with data on the breast cancer hazard function, breast cancer lethality can be estimated at each of the 15 years after diagnosis. A web-based calculator was then created to visualize the estimated lethality with and without a range of adjuvant therapy options at any of the 15 years after diagnosis, and enable conditional survival calculations. NIH population data was used to estimate non-breast-cancer chance of death. The accuracy of the calculators was tested against two large breast carcinoma datasets: 7,907 patients seen at two academic hospitals and 362,491 patients from the SEER national dataset. The calculators were found to be highly accurate and specific, as seen by their capacity for stratifying patients into groups differing by as little as a 2% risk of death, and accurately accounting for nodal status, histology, grade, age, and hormone receptor status. Our breast carcinoma calculators provide accurate and useful estimates of the risk of death, which can aid in analysis of the various adjuvant therapy options available to each patient.
KeywordsBreast cancer Survival Outcome Calculator Epidemiology Conditional survival Hazard function
Work in this article was supported through funds from the Department of Surgical Oncology at Massachusetts General Hospital.
Conflicts of interest
- 4.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 365(9472):1687–1717CrossRefGoogle Scholar
- 6.Michaelson JS, Technical Report #1—Mathematical Methods (March 9, 2009). http://cancer.lifemath.net/about/techreports/index.php
- 10.Michaelson JS, Technical Report #12—2nd Technical report for the paper: “CancerMath.net: Wed-based Calculators for Breast Carcinoma” (June 17, 2010). http://cancer.lifemath.net/about/techreports/index.php
- 12.Chen LL, and Michaelson JS (2009) Technical Report #9—Adjuvant Multi-agent Chemotherapy and Tamoxifen Usage Trends for Breast Cancer in the United States (March 27). http://cancer.lifemath.net/about/techreports/technical_report_9.pdf
- 16.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual, 7th edn. Springer, BerlinGoogle Scholar
- 18.Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer Leukemia, Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977PubMedCrossRefGoogle Scholar
- 23.Michaelson J (2007) Mammographic screening: impact on survival. In: Hayat MA (ed) Cancer imaging. Elsevier, AmsterdamGoogle Scholar
- 24.National Vital Statistics Reports Vol. 54 No. 14, April 19, 2006, United States Life Tables (2003)Google Scholar